{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T10:53:25Z","timestamp":1648637605299},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,5,23]],"date-time":"2016-05-23T00:00:00Z","timestamp":1463961600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s00059-016-4434-4","type":"journal-article","created":{"date-parts":[[2016,5,24]],"date-time":"2016-05-24T03:48:05Z","timestamp":1464061685000},"page":"290-295","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["PCSK9-Inhibitoren"],"prefix":"10.1007","volume":"41","author":[{"given":"D.","family":"M\u00fcller-Wieland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Marx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,23]]},"reference":[{"key":"4434_CR1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","volume":"161","author":"JL Goldstein","year":"2015","unstructured":"Goldstein JL, Brown MS (2015) A century of cholesterol and coronaries: from plaques to genes to statins. Cell 161:161\u2013172","journal-title":"Cell"},{"key":"4434_CR2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0092-8674(77)90022-8","volume":"10","author":"RGW Anderson","year":"1977","unstructured":"Anderson RGW, Brown MS, Goldstein JL (1977) Role oft he coated endocytic vesicle in the uptake of receptor-bound low density lipoprotein in human fibroblasts. Cell 10:351\u2013364","journal-title":"Cell"},{"key":"4434_CR3","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/279679a0","volume":"279","author":"JL Goldstein","year":"1979","unstructured":"Goldstein JL, Anderson RGW, Brown MS (1979) Coated pits, coated vesicles, and receptor-mediated endocytosis. Nature 279:679\u2013685","journal-title":"Nature"},{"key":"4434_CR4","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","volume":"282","author":"DW Zhang","year":"2007","unstructured":"Zhang DW, Lapace TA, Garuti R, Zhao Z et al (2007) Binding of proprotein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J\u00a0Biol Chem 282:18602\u201318612","journal-title":"J Biol Chem"},{"key":"4434_CR5","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","volume":"50","author":"JD Horton","year":"2009","unstructured":"Horton JD, Cohen JC, Hobbs HH (2009) PCSK9: a convertase that coordinates LDL catabolism. J\u00a0Lipid Res 50:S172\u2013S177","journal-title":"J Lipid Res"},{"key":"4434_CR6","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M, Varret M, Rabes J\u2011P, Allard D et al (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34:154\u2013156","journal-title":"Nat Genet"},{"key":"4434_CR7","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH (2006) Sequence varaiations in PCSK9, low LDL, and protection agaimst coronary heart disease. N\u00a0Engl J Med 354:1264\u20131272","journal-title":"N Engl J Med"},{"key":"4434_CR8","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","volume":"114","author":"NG Seidah","year":"2014","unstructured":"Seidah NG, Awan Z, Chretien M, Mbikay M (2014) PCSK9: a key modulator of cardiovascular health. Circ Res 114:1022\u20131036","journal-title":"Circ Res"},{"key":"4434_CR9","author":"R Schulz","year":"2015","unstructured":"Schulz R, Schl\u00fcter K\u2011D, Laufs U (2015) Molecular and cellular function of the proprotein convertase subtilisin\/kexin type 9 (PCSK9). Basic Res Cardiol. doi:10.1007\/s00395-015-0463-z","journal-title":"Basic Res Cardiol"},{"key":"4434_CR10","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M et\u00a0al (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372:1489\u20131499","journal-title":"N Engl J Med"},{"key":"4434_CR11","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD et\u00a0al (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372:1500\u20131509","journal-title":"N Engl J Med"},{"key":"4434_CR12","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","volume":"9","author":"PM Moriarty","year":"2015","unstructured":"Moriarty PM, Thompson PD, Cannon CP et al (2015) Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patienets, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol 9:758\u2013769","journal-title":"J Clin Lipidol"},{"key":"4434_CR13","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"ES Stroes","year":"2015","unstructured":"Stroes ES, Thompson PD, Corsini A et al (2015) Statin-associated muscle symptoms: impact on statin therapy \u2013 European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 36:1012\u20131022","journal-title":"Eur Heart J"},{"key":"4434_CR14","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","volume":"63","author":"E Stroes","year":"2014","unstructured":"Stroes E, Colquhoun D, Sullivan D et al (2014) Anti-PCSK9 antibody effectively lowers cholesterol in patients with atatin intolerance: The GAUSS-2 randomized, placebo-controlled phse 3 clinical trial of evolocumab. J Am Coll Cardiol 63:2541\u20132548","journal-title":"J Am Coll Cardiol"},{"key":"4434_CR15","first-page":"2996","volume":"43","author":"JJ Kastelein","year":"2015","unstructured":"Kastelein JJ, Ginsberg HN, Langslet G et\u00a0al (2015) ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolemia. Eur Heart J 43:2996\u20133003","journal-title":"Eur Heart J"},{"key":"4434_CR16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","volume":"385","author":"FJ Raal","year":"2015","unstructured":"Raal FJ, Stein EA, Dufour R et al (2015) PCSK9 inhibition with eveocumab (AMG 145) in heterozygous familial hypercholesterolemia: (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 385:331\u2013340","journal-title":"Lancet"},{"key":"4434_CR17","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"F Raal","year":"2012","unstructured":"Raal F, Scott R, Somaratne R, Bridges I et al (2012) Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesetrolemia Disorder (RUTHERFORD) randomized trial. Circulation 126:2408\u20132417","journal-title":"Circulation"},{"key":"4434_CR18","author":"PM Moriarty","year":"2016","unstructured":"Moriarty PM, Parhofer KG, Babirak SP et\u00a0al (2016) Alirocumab in patienets with heterozygous familial hypercholesterolemia undergoing lipoprotein apharesis: Rationale and design oft he ODYSSEY ESCAPE trial. J\u00a0Clin Lipidol. doi:10.1016\/j.jacl.2016.02.003","journal-title":"J Clin Lipidol"},{"key":"4434_CR19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jacl.2014.07.007","volume":"8","author":"TA Jacobson","year":"2014","unstructured":"Jacobson TA, Matthew KI, Kevin CM et al (2014) NLA National Lipid Association recommendations for patient-centered management of dyslipidemia: Part1-executive summary. J Clin Lipidol 8:473\u2013488","journal-title":"J Clin Lipidol"},{"issue":"25 Suppl 2","key":"4434_CR20","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","volume":"129","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH et\u00a0al (2014) 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force to practice guidelines. Circulation 129(25 Suppl 2):S1\u2013S45","journal-title":"Circulation"},{"key":"4434_CR21","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"Z Reiner","year":"2011","unstructured":"Reiner Z, Catapano AL, De Backer G et\u00a0al (2011) ESC\/EAS guidelines for the management of dyslipidemias. Eur Heart J 32:1769\u20131818","journal-title":"Eur Heart J"},{"key":"4434_CR22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/2047487314567001","volume":"23","author":"D M\u00fcller-Wieland","year":"2016","unstructured":"M\u00fcller-Wieland D, Assmann G, Carmena R et al (2016) Treat-to-target versus dose-adapted statin treatment of cholesterol to reduce cardiovascular risk. Eur J Prev Cardiol 23:275\u2013281","journal-title":"Eur J Prev Cardiol"},{"key":"4434_CR23","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.297.5.499","volume":"297","author":"SJ Nicholls","year":"2007","unstructured":"Nicholls SJ, Tuzcu EM, Sipahi I et\u00a0al (2007) Statins, high density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 297:499\u2013508","journal-title":"JAMA"},{"key":"4434_CR24","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","volume":"291","author":"SE Nissen","year":"2004","unstructured":"Nissen SE, Tuszu EM, Schoenhagen P et al (2004) Effect of intense compared with moderate blipid-lowering therapy on progression of coronary atherosclerosis: a randomised controlled trial. JAMA 291:1071\u20131080","journal-title":"JAMA"},{"key":"4434_CR25","first-page":"748","volume":"112","author":"U Laufs","year":"2015","unstructured":"Laufs U, Scharnagl H, Halle M et al (2015) Behandlungsoptionen bei Statin-assoziierten Muskelbeschwerden. Dtsch Arztebl Int 112:748\u2013755","journal-title":"Dtsch Arztebl Int"},{"key":"4434_CR26","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1093\/eurheartj\/ehv157","volume":"36","author":"A Wiegman","year":"2015","unstructured":"Wiegman A, Gidding SS, Watts GF, Chapman MJ et\u00a0al (2015) Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J 36:2425\u20132437","journal-title":"Eur Heart J"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-016-4434-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00059-016-4434-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-016-4434-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T11:52:45Z","timestamp":1558525965000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00059-016-4434-4"}},"subtitle":["Neue Therapieoption im klinischen Alltag"],"short-title":[],"issued":{"date-parts":[[2016,5,23]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["4434"],"URL":"https:\/\/doi.org\/10.1007\/s00059-016-4434-4","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"value":"0340-9937","type":"print"},{"value":"1615-6692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,23]]}}}